Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

Skarbaliene J, Mathiesen JM, Larsen BD, Thorkildsen C, Petersen YM

BMC gastroenterology21 Mar 2023Cited by 11 (Europe PMC)

PMID36944922PMCIDPMC10029296DOI10.1186/s12876-023-02716-4PepBankPUB-36944922

Summary

BackgroundGlucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for treatment of short bowel syndrome. Here, we investigated if glepaglutide is therapeutically beneficial in rats with small intestinal inflammation.MethodsSmall intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages. Glepaglutide was administered in co-treatment and post-treatment regimens. Small intestinal length and concentrations of inflammatory markers α-1-acid glycoprotein and myeloperoxidase were used to assess anti-inflammatory effects. Small intestinal mass was evaluated to determine intestinotrophic effects.ResultsGlepaglutide co- and post-treatment significantly reduced severity of small intestinal inflammation, evidenced by reversed small intestinal shortening and decreased α-1-acid glycoprotein and/or myeloperoxidase concentration(s). Co- and post-treatment with glepaglutide also significantly increased small intestinal mass, indicating intestinal regenerative effects. Similar effects were observed in naive rats after glepaglutide treatment.ConclusionGlepaglutide has anti-inflammatory and intestinotrophic effects without the need for pre-treatment in a rat model of small intestinal inflammation. Thus, glepaglutide is of potential clinical interest for patients with IBD.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with intestinal inflammation, glepaglutide co- and post-treatment significantly reduced inflammation severity.
In plain wordsIn rats with intestinal inflammation, glepaglutide co- and post-treatment significantly reduced inflammation severity.
Peptide
Glepaglutide
Outcome
DecreaseSmall intestinal inflammation severity
Study
Wistar ratsn: not reported in source
Indomethacin-induced small intestinal inflammation
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Glepaglutide co- and post-treatment significantly reduced severity of small intestinal inflammation, evidenced by reversed small intestinal shortening and decreased α-1-acid glycoprotein and/or myeloperoxidase concentration(s).
2 context sentences(design, population, supporting numbers)
Summary · context
Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages.
Summary · context
Glepaglutide was administered in co-treatment and post-treatment regimens.
Show in the study text Report a problemFND-3694492201
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with intestinal inflammation, glepaglutide co- and post-treatment reversed small intestinal shortening.
In plain wordsIn rats with intestinal inflammation, glepaglutide co- and post-treatment reversed small intestinal shortening.
Peptide
Glepaglutide
Outcome
DecreaseSmall intestinal shortening
Study
Wistar ratsn: not reported in source
Indomethacin-induced small intestinal inflammation
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Glepaglutide co- and post-treatment significantly reduced severity of small intestinal inflammation, evidenced by reversed small intestinal shortening and decreased α-1-acid glycoprotein and/or myeloperoxidase concentration(s).
2 context sentences(design, population, supporting numbers)
Summary · context
Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages.
Summary · context
Glepaglutide was administered in co-treatment and post-treatment regimens.
Show in the study text Report a problemFND-3694492202
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with intestinal inflammation, glepaglutide co- and post-treatment decreased α-1-acid glycoprotein and/or myeloperoxidase concentrations.
In plain wordsIn rats with intestinal inflammation, glepaglutide decreased α-1-acid glycoprotein and/or myeloperoxidase concentrations.
Peptide
Glepaglutide
Outcome
Decreaseα-1-acid glycoprotein and/or myeloperoxidase concentrations
Study
Wistar ratsn: not reported in source
Indomethacin-induced small intestinal inflammation
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Glepaglutide co- and post-treatment significantly reduced severity of small intestinal inflammation, evidenced by reversed small intestinal shortening and decreased α-1-acid glycoprotein and/or myeloperoxidase concentration(s).
2 context sentences(design, population, supporting numbers)
Summary · context
Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages.
Summary · context
Glepaglutide was administered in co-treatment and post-treatment regimens.
Show in the study text Report a problemFND-3694492203
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with intestinal inflammation, glepaglutide co- and post-treatment significantly increased small intestinal mass.
In plain wordsIn rats with intestinal inflammation, glepaglutide co- and post-treatment significantly increased small intestinal mass.
Peptide
Glepaglutide
Outcome
IncreaseSmall intestinal mass
Study
Wistar ratsn: not reported in source
Indomethacin-induced small intestinal inflammation
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Co- and post-treatment with glepaglutide also significantly increased small intestinal mass, indicating intestinal regenerative effects.
2 context sentences(design, population, supporting numbers)
Summary · context
Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages.
Summary · context
Glepaglutide was administered in co-treatment and post-treatment regimens.
Show in the study text Report a problemFND-3694492204
05AnimalAnimal study (in vivo)Efficacy outcome
In naive rats, glepaglutide produced similar effects, without separate outcome estimates in the abstract.
In plain wordsIn naive rats, glepaglutide produced similar intestinal effects, without separate outcome estimates.
Peptide
Glepaglutide
Outcome
Direction not reportedSimilar intestinal effects in naive rats
Study
Wistar ratsn: not reported in source
Naive rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Similar effects were observed in naive rats after glepaglutide treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Co- and post-treatment with glepaglutide also significantly increased small intestinal mass, indicating intestinal regenerative effects.
Summary · context
Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages.
Summary · context
Glepaglutide was administered in co-treatment and post-treatment regimens.
Show in the study text Report a problemFND-3694492205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.